FreeTheAI

Propanc Biopharma Publishes Pilot Study Data on Cancer Proenzyme Treatment

BullishMedium impact
PPCB$0.4401 6.69%

Propanc Biopharma, Inc. (NASDAQ:PPCB) has published results from a peer-reviewed pilot study evaluating its drug candidate, PRP. The experimental therapy uses a 1:6 ratio of pancreatic proenzymes trypsinogen and chymotrypsinogen A to target cancer stem cells. In laboratory testing across 24 human cancer cell lines, the combination inhibited tumor growth, reduced cell migration, and blocked blood vessel formation that feeds tumors.

In animal models, daily intravenous administration of PRP produced an 85.9% reduction in pancreatic tumor weight at higher doses and roughly a 50% weight reduction in ovarian cancer models, with no treatment-related adverse events. Additionally, early human clinical observations involving 46 patients with advanced cancers showed an average survival time of 9.0 months compared to an expected 5.6 months, with over 41% of participants outliving their predicted life expectancies.

Investors should monitor the company's progress as it moves forward with development for pancreatic, ovarian, and refractory prostate cancers. Key milestones will include further clinical trials to confirm whether PRP can effectively lower the risk of cancer recurrence and metastasis in larger patient populations.

Key points

  • Propanc Biopharma published pilot study data evaluating its PRP proenzyme formulation for pancreatic and ovarian cancer.
  • Animal testing demonstrated an 85.9% reduction in pancreatic tumor weight and roughly a 50% reduction in ovarian tumor weight.
  • Human observational data showed treated patients achieved a mean survival of 9.0 months compared to an expected 5.6 months.
  • The therapy was well tolerated with no serious treatment-related adverse events reported in animal or human evaluations.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did Propanc Biopharma's study show for pancreatic cancer?

In animal models, PRP achieved an 85.9% reduction in mean tumor weight at higher doses. In human observational data, treated patients with advanced cancers had a mean survival of 9.0 months compared to the expected 5.6 months.

What is Propanc Biopharma's PRP formulation?

PRP is a proprietary fixed-ratio combination of two pancreatic proenzymes, trypsinogen and chymotrypsinogen A (1:6 ratio), designed to eradicate cancer stem cells and lower the risk of tumor recurrence and metastasis.

What cancers is Propanc Biopharma targeting with PRP?

Propanc Biopharma is primarily targeting pancreatic, ovarian, and refractory prostate cancers, which are areas with high unmet medical needs and limited treatment options.